Nurix Therapeutics, Inc. (NRIX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 11, 2026, by Nurix Therapeutics, Inc. The filing discloses updated clinical data from the Phase 1a/1b study of bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, to be presented at the European Hematology Association Congress (EHA2026). The data focuses on patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data Updates
The filing details significant updates to the Phase 1a/1b study as of the January 1, 2026 data cutoff:
- Safety Profile: The study included 142 patients with CLL/SLL (86 at the 600 mg dose). Bexobrutideg was well tolerated with no dose-limiting toxicities. The most common treatment-emergent adverse events were purpura/contusion, neutropenia, petechiae, diarrhea, and fatigue. Three Grade 5 adverse events were reported but deemed unrelated to treatment.
- Phase 1a Efficacy (Relapsed/Refractory): Among 47 response-evaluable patients with a median follow-up of 22.4 months, the objective response rate (ORR) was 83.0%. This included 4.3% complete response and 76.6% partial response. Median progression-free survival was 22.1 months. Responses were observed in high-risk subgroups, including those with BTK inhibitor resistance mutations and CNS involvement.
- Phase 1b Earlier-Line Cohorts:
- Cohort 5 (BTKi-treated, BCL2i-naïve): 19 patients enrolled; ORR of 92.9% among 14 evaluable patients (median follow-up 5.2 months).
- Cohort 15 (BTKi-naïve, including treatment-naïve): 20 patients enrolled; ORR of 84.2% among 19 evaluable patients (median follow-up 4.9 months).
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or forward-looking statements regarding revenue or timelines beyond the clinical data presentation. The primary risk context relates to the clinical development of bexobrutideg, noting that while the drug showed efficacy in difficult-to-treat populations, the data is from a Phase 1 study. The filing explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not an admission of materiality.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical tables and confidence intervals.
- Confirm the specific definitions of "response-evaluable" patients used in the ORR calculations.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor upcoming presentations at EHA2026 for any additional data not summarized in this filing.
- Assess the competitive landscape for BTK degraders given the high ORR in BTKi-resistant populations.